公开(公告)号：US11339199B2

公开(公告)日：2022-05-24

申请号：US16458740

申请日：2019-07-01

申请人： TRUSTEES OF DARTMOUTH COLLEGE

发明人： Tong Zhang ,  Charles L. Sentman

IPC分类号： A61K35/17 ,  C07K14/705 ,  A61K38/10 ,  C07K14/715 ,  A61K45/06

摘要： The present invention relates to chimeric immune receptor molecules for reducing or eliminating tumors. The chimeric receptors are composed a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif. Methods for using the chimeric receptors are further provided.

公开(公告)号：US11267897B2

公开(公告)日：2022-03-08

申请号：US16173114

申请日：2018-10-29

申请人： INNATE PHARMA

发明人： Laurent Gauthier ,  Nadia Anceriz ,  Ariane Morel ,  Benjamin Rossi

IPC分类号： A61P43/00 ,  C07K16/28 ,  C12N15/62

摘要： Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.

公开(公告)号：US11266973B2

公开(公告)日：2022-03-08

申请号：US16319493

申请日：2017-08-08

申请人： KEMIRA OYJ

发明人： David Goult ,  Simon Naylor ,  Dave Tuff

IPC分类号： B01J19/22

摘要： The invention relates to an arrangement for continuous production of polymer including a polymerisation reactor. The reactor includes a first pulley and a second pulley arranged at a distance from each other, which distance, defining a longitudinal first direction, and a flexible endless belt having a first edge section and a second edge section, which belt, is arranged to travel over the first pulley and the second pulley as a flat belt. The reactor further includes a supporting structure, which is arranged to support the flexible endless belt between the first pulley and the second pulley, whereby the supporting structure is arranged to form the flexible endless belt into a trough section by deviating the first edge section and the second edge section of the flexible endless belt away from the first direction. The trough section has a width-to-height ratio

公开(公告)号：US11254741B2

公开(公告)日：2022-02-22

申请号：US16242792

申请日：2019-01-08

申请人： ALDER BIOPHARMACEUTICALS, INC.

发明人： Maria-Cristina Loomis ,  Leon F. Garcia-Martinez ,  Benjamin H. Dutzar ,  Daniel S. Allison ,  Katherine Lee Hendrix ,  Ethan W. Ojala ,  Pei Fan ,  Jeffrey T. L. Smith ,  John A. Latham ,  Charlie Karasek ,  Jenny Mulligan ,  Michelle Scalley-Kim ,  Erica Stewart ,  Vanessa Lisbeth Rubin ,  Jens J. Billgren

IPC分类号： C07K16/26 ,  A61K39/395 ,  C07K14/575 ,  A61P25/06 ,  G01N33/50 ,  A61K45/06 ,  G01N33/74 ,  A61K39/00 ,  C07K16/42 ,  A61K49/00

摘要： The present invention is directed to antagonistic antibodies and antigen binding fragments thereof having binding specificity for PACAP. These antibodies inhibit, block or neutralize at least one biological effect associated with PACAP, e.g., vasodilation. In exemplary embodiments these antibodies and antigen binding fragments thereof may comprise specific VH, VL, and CDR polypeptides described herein. In some embodiments these antibodies and antigen binding fragments thereof bind to and/or compete for binding to specific epitope(s) on human PACAP. The invention is further directed to using these antagonistic anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, mast cell degranulation, and/or neuronal activation, are therapeutically beneficial, e.g., headache and migraine indications.

公开(公告)号：US11224634B2

公开(公告)日：2022-01-18

申请号：US17198939

申请日：2021-03-11

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Gene M. Dubowchik ,  Olafur S. Gudmundsson ,  Xiaojun Han ,  R. Michael Lawrence ,  Dasa Lipovsek ,  Cort S. Madsen ,  Claudio Mapelli ,  Paul E. Morin ,  Michael C. Myers

IPC分类号： A61K38/22 ,  A61K38/18 ,  C07K14/64 ,  C07K1/107 ,  A61K38/00 ,  A61K47/64 ,  A61P9/00 ,  A61K45/06

摘要： The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.

公开(公告)号：US11208454B2

公开(公告)日：2021-12-28

申请号：US16415309

申请日：2019-05-17

申请人： TRUSTEES OF DARTMOUTH COLLEGE

发明人： Tong Zhang ,  Charles L. Sentman

IPC分类号： C07K14/47 ,  C07K14/705 ,  A61K38/10 ,  C07K14/715 ,  A61K35/17 ,  A61K45/06

摘要： The present invention relates to chimeric immune receptor molecules for reducing or eliminating tumors. The chimeric receptors are composed a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif. Methods for using the chimeric receptors are further provided.

公开(公告)号：US11185570B2

公开(公告)日：2021-11-30

申请号：US16287342

申请日：2019-02-27

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Gene M. Dubowchik ,  Olafur S. Gudmundsson ,  Xiaojun Han ,  R. Michael Lawrence ,  Dasa Lipovsek ,  Cort S. Madsen ,  Claudio Mapelli ,  Paul E. Morin ,  Michael C. Myers

IPC分类号： A61K38/18 ,  C07K14/64 ,  C07K1/107 ,  A61K38/00 ,  A61K47/64 ,  A61P9/00 ,  A61K45/06

摘要： The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.

公开(公告)号：USD931477S1

公开(公告)日：2021-09-21

申请号：US29728739

申请日：2020-03-20

申请人： Lindsey Ferrell

设计人： Lindsey Ferrell

公开(公告)号：US11111162B2

公开(公告)日：2021-09-07

申请号：US16988760

申请日：2020-08-10

申请人： KEMIRA OYJ

发明人： Thomas Fenderson ,  Miguel Pelaez ,  Igal Maasen ,  Yuping Luo

IPC分类号： C02F1/56 ,  C02F1/52 ,  C02F1/38 ,  C02F1/00 ,  C02F103/10

摘要： A method for treating tailings substrate from mining or oil sands separation process, the tailings substrate comprising an aqueous phase with suspended solid particulate material. In the method, a flocculating agent is added to the tailings substrate, flocs are allowed to form and the formed flocs are separated from the aqueous phase. The flocculating agent comprises a degraded polyacrylamide comprising at least anionic units and having a process water viscosity reduced by 25-99%, preferably 50-99%, compared to a substantially similar polyacrylamide that has not been degraded by a degradation agent, measured at a shear rate 1 s−1 as a 0.4-0.8 weight-% solution of polymer in process water.

公开(公告)号：US11040064B2

公开(公告)日：2021-06-22

申请号：US15554762

申请日：2016-03-17

申请人： Pharmacosmos Holding A/S

发明人： Lars Lykke Thomsen ,  Tobias S. Christensen ,  Hans Andreasen

IPC分类号： A61K33/26 ,  A61K47/61

摘要： The present invention relates to pharmaceutical composition comprising an iron carbohydrate complex for use in a method for treatment or prevention of Restless Leg Syndrome (RLS) of a human patient, wherein the human patient prior to treatment has a magnetic resonance phase imaging of 0.02 radians above the average value of a control group in the substantia nigra, thalamus, putamen, orpallidum. The invention provides a higher probability for a RLS patient being treated to experience a relief in symptoms.